The capital return plan (up to ~$230M) and the Moderna settlement cash provide a significant floor for the stock. Monitor for the specific form of share repurchases (tender offer vs open market) and any updates on the Pfizer/BioNTech LNP lawsuits, which could unlock additional value. The operational quarter is irrelevant — trade on the capital allocation and litigation catalysts.
Price Chart
Executive Summary
Arbutus Biopharma reported Q2 2026 revenue of $1.0M (down from $10.7M YoY due to the prior year's Qilu partnership revenue recognition) and a net loss of $5.1M (-$0.03 EPS), in line with consensus. The quarter was overshadowed by the receipt of $178.4M from the Moderna settlement in July and a plan to return up to ~$230M to shareholders via share repurchases, alongside new LNP patent lawsuits against Pfizer/BioNTech. The stock will move on the capital return plan and litigation catalysts, not the operational results.
Key Financial Metrics
Key Facts
- Received $178.4M from Moderna settlement in July 2026 as share of $950M noncontingent payment
- Plans to return up to ~$230M to shareholders via share repurchases, potentially including a Dutch Auction tender offer
- Filed three international LNP patent lawsuits against Pfizer/BioNTech across 21 countries
- Q2 2026 revenue $1.0M vs $10.7M YoY; net loss $5.1M (-$0.03 EPS) vs net income $2.5M ($0.01 EPS) YoY
- Cash and marketable securities $92.6M as of June 30, 2026, plus $179.4M receivable from Genevant license
- FDA Fast Track designation for imdusiran in chronic hepatitis B; alignment on Phase 2b trial design
Financial Impact
Capital return of up to ~$230M (25% of current market cap) plus $178.4M cash infusion from Moderna settlement
Risk Factors
- Capital return plan is subject to board approval and may not occur in Q3 2026 or at all
- Pfizer/BioNTech lawsuits face uncertain outcomes and could be protracted
- Imdusiran Phase 2b trial may not meet endpoints or receive regulatory approval
- Contingent $1.3B Moderna payment depends on appellate ruling on 28 U.S.C. §1498
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343555 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | 8-K | $5.21 $5.00 | ▼ −4.03% | ▼ −3.50% | $4.45 (−14.59%) |
Aug 15, 2026 6w ago | Institutional Cluster | $4.71 $5.06 | ▲ +7.43% | ▲ +9.41% | $4.45 (−5.52%) |
Aug 12, 2026 7w ago | 8-K | $4.59 $5.12 | ▲ +11.55% | ▲ +13.44% | $4.45 (−3.05%) |
Aug 12, 2026 7w ago | Press Release | $4.59 $5.12 | ▲ +11.55% | ▲ +13.44% | $4.45 (−3.05%) |
Jul 16, 2026 11w ago | 8-K | $4.74 $4.58 | ▼ −3.38% | ▼ −6.99% | $4.45 (−6.12%) |
Jun 12, 2026 16w ago | Institutional Cluster | $4.26 $4.80 | ▲ +12.68% | ▲ +10.90% | $4.45 (+4.46%) |
May 13, 2026 20w ago | 8-K | $4.31 $4.29 | ▼ −0.46% | ▲ +0.15% | $4.45 (+3.25%) |
May 13, 2026 20w ago | Press Release | $4.31 $4.29 | ▼ −0.46% | ▲ +0.15% | $4.45 (+3.25%) |
Apr 15, 2026 24w ago | 8-K | $4.48 $4.31 | ▼ −3.79% | ▼ −9.84% | $4.45 (−0.67%) |
Mar 23, 2026 27w ago | Press Release | $4.42 $4.43 | ▲ +0.23% | ▼ −7.19% | $4.45 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access